Late-onset Pompe: Why respiratory distress often fools us

Written by The Life Science Feed Editorial Team · Published 14 September 2026 · Edited by Mara Voss

Late-onset Pompe disease (LOPD) is a rare, progressive neuromuscular disorder that often masquerades as more common conditions, leading to significant diagnostic delays. The insidious onset of symptoms, particularly respiratory dysfunction preceding noticeable limb weakness, creates a critical window for intervention that is frequently missed. Understanding the early respiratory manifestations is paramount for clinicians, especially those in general practice and pulmonology, to accelerate diagnosis and initiate appropriate management.

KEY TAKEAWAYS

- The Pivot: Respiratory symptoms, particularly nocturnal hypoventilation and exertional dyspnea, frequently precede overt limb girdle weakness in LOPD.
- The Data: Early recognition of these respiratory signs can reduce the average diagnostic delay, which often spans years.
- The Action: Clinicians should consider LOPD in patients presenting with unexplained progressive respiratory insufficiency, even in the absence of significant motor deficits.

Late-onset Pompe disease, a glycogen storage disorder type II, results from a deficiency of acid alpha-glucosidase (GAA), a lysosomal enzyme responsible for breaking down glycogen. This enzyme deficiency leads to the accumulation of glycogen primarily in skeletal, cardiac, and smooth muscles, causing progressive muscle weakness and dysfunction. While the infantile form is rapidly progressive and often fatal without early intervention, LOPD presents later in life, typically from childhood into adulthood, with a much slower and more variable disease course. The variability in presentation makes LOPD a diagnostic challenge, frequently leading to misdiagnosis as muscular dystrophy, limb-girdle weakness, or even idiopathic respiratory failure. The average diagnostic delay can extend for many years, during which irreversible muscle damage can accumulate, particularly affecting the diaphragm and other respiratory muscles.
The underlying pathophysiology in LOPD involves the progressive accumulation of lysosomal glycogen within muscle cells. This accumulation disrupts cellular function, leading to myopathy and muscle fiber degeneration. The diaphragm and intercostal muscles are particularly vulnerable, making respiratory compromise a hallmark of the disease. The clinical spectrum of LOPD is broad, but a consistent pattern emerges where respiratory symptoms often manifest before the more commonly recognized limb girdle weakness becomes debilitating. This early respiratory involvement is a critical, yet often overlooked, diagnostic clue. Patients may initially report non-specific symptoms such as fatigue, morning headaches, or daytime somnolence, which are often attributed to other conditions like sleep apnea or chronic obstructive pulmonary disease (COPD). A detailed history, however, often reveals a progressive decline in respiratory function that predates significant mobility issues.

The Insidious Onset of Respiratory Dysfunction

The respiratory manifestations of LOPD are often subtle at first, progressing gradually over years. Diaphragmatic weakness is a primary concern, leading to reduced lung volumes and impaired cough reflex. Patients may experience exertional dyspnea, which can be initially dismissed as deconditioning or age-related decline. Nocturnal hypoventilation is another early and critical sign, often presenting as disturbed sleep, morning headaches, daytime fatigue, and unrefreshing sleep. These symptoms arise from the diaphragm's inability to maintain adequate ventilation during sleep, particularly in supine positions, leading to hypercapnia. The cough assessment gap in respiratory disease is particularly relevant here, as a weak cough can lead to recurrent respiratory infections, further complicating the clinical picture.
Pulmonary function tests (PFTs) are essential for evaluating respiratory involvement. A restrictive ventilatory defect is typical, characterized by reduced forced vital capacity (FVC) and total lung capacity (TLC). Critically, FVC measured in both supine and upright positions can reveal diaphragmatic weakness. A significant drop in FVC (typically >10-20%) when moving from an upright to a supine position is highly suggestive of diaphragmatic dysfunction, a key indicator of LOPD. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) are also often reduced, reflecting inspiratory and expiratory muscle weakness. These objective measures can provide concrete evidence of respiratory muscle involvement long before a patient requires ventilatory support.

Beyond Limb Weakness: Recognizing the Broader Picture

While limb girdle weakness is a defining feature of LOPD, its late onset often delays diagnosis. Patients typically present with progressive weakness in the proximal muscles of the hips and shoulders, leading to difficulty climbing stairs, rising from a chair, or lifting objects. This weakness is often symmetrical but can be asymmetric in some cases, further complicating differentiation from other myopathies. The progression is slow, allowing patients to adapt to their limitations, which can inadvertently prolong the diagnostic journey. The late-onset presentations in adult clinics are a common theme across many rare diseases, and Pompe is no exception.

Beyond respiratory and limb weakness, other systems can be affected. Gastrointestinal involvement, such as dysphagia and constipation, can occur due to smooth muscle weakness. Cardiac involvement, while less common and severe than in infantile Pompe disease, can manifest as arrhythmias or mild cardiomyopathy in some LOPD patients. The skeletal system can also be affected, with increased risk of scoliosis and osteoporosis due to chronic muscle weakness and reduced mobility. These systemic manifestations, though less prominent than the primary muscle weakness, contribute to the overall disease burden and can provide additional diagnostic clues when considered in conjunction with respiratory and motor symptoms.

Diagnostic Pathways and Enzyme Replacement Therapy

The diagnostic pathway for LOPD typically begins with a high index of suspicion based on clinical presentation, particularly the combination of unexplained progressive respiratory insufficiency and proximal muscle weakness. Initial screening often involves PFTs, creatine kinase (CK) levels (which may be elevated but can also be normal), and electromyography (EMG), which can show myopathic changes. The definitive diagnosis relies on demonstrating deficient GAA enzyme activity in dried blood spots (DBS), fibroblasts, or muscle biopsies. Genetic testing for mutations in the GAA gene confirms the diagnosis and can also help predict disease severity and progression. Given the rarity of the disease, a clinician might consult an Oxford Handbook of Genetics for guidance on testing protocols and interpretation.

Enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase is the established standard of care for LOPD. Early initiation of ERT is essential to maximize therapeutic benefit and slow disease progression, particularly in preserving respiratory function. Studies have shown that ERT can stabilize or improve FVC, reduce the need for ventilatory support, and enhance motor function and quality of life. But the efficacy of ERT is greater when initiated before significant irreversible muscle damage has occurred, underscoring the importance of early diagnosis. The long diagnostic delays currently observed mean many patients begin ERT when their disease is already advanced, limiting the potential for full recovery.

Challenges in Diagnosis and Management

The primary challenge in LOPD diagnosis remains its rarity and the non-specific nature of early symptoms. Many clinicians, particularly in primary care, may not consider LOPD in the differential diagnosis for patients presenting with fatigue, dyspnea, or mild muscle weakness. This leads to extensive workups for more common conditions, delaying the correct diagnosis. The lack of awareness among healthcare professionals about the early respiratory signs of LOPD is a significant barrier. Education campaigns targeting pulmonologists, neurologists, and general practitioners are essential to improve diagnostic rates.

Another challenge lies in the interpretation of diagnostic tests. While DBS screening for GAA activity is a relatively simple and non-invasive test, false negatives can occur, especially in patients with residual enzyme activity. Confirmatory testing in fibroblasts or muscle biopsy is often necessary. The genetic heterogeneity of LOPD means that some patients may have novel mutations that are not immediately recognized, requiring expert genetic interpretation. The progressive nature of the disease also means that ongoing monitoring of respiratory and motor function is critical, even after diagnosis and initiation of ERT. Regular PFTs, sleep studies, and motor assessments are necessary to track disease progression and adjust management strategies. For a comprehensive overview of respiratory conditions, the Oxford Handbook of Respiratory Medicine can be a valuable resource.

The open-label design of many early ERT studies is an obvious caveat, but the consistent clinical improvements observed across various cohorts provide a strong argument for its efficacy. The trial was not powered to detect differences in specific genetic subgroups, and that gap matters for understanding optimal dosing and long-term outcomes in diverse patient populations. Whether benefits extend to patients with very advanced disease and severe respiratory failure remains unclear, as most studies focus on earlier intervention. More robust, long-term, controlled studies are needed to fully elucidate the optimal timing and duration of ERT, as well as its impact on rare manifestations and quality of life. The field still needs to define clear biomarkers that predict response to therapy and disease progression more accurately than current clinical measures.

CLINICAL IMPLICATIONS

The persistent diagnostic delays in late-onset Pompe disease are a clinical failure, plain and simple. When respiratory symptoms like exertional dyspnea or nocturnal hypoventilation appear years before overt limb weakness, primary care physicians and pulmonologists are on the front line. They must be equipped to recognize these subtle cues, rather than defaulting to more common diagnoses that waste precious time.

The current standard of care, enzyme replacement therapy, works best when initiated early. But if patients are spending years navigating a diagnostic odyssey, they are losing valuable time during which irreversible muscle damage accrues. This directly impacts the potential efficacy of treatment and the patient's long-term quality of life. We need to see a concerted effort to raise awareness among specialists who are likely to encounter these patients first.

For industry, the challenge is to support earlier diagnosis through educational initiatives and accessible screening tools. A simple dried blood spot test for GAA activity could be integrated more broadly into diagnostic algorithms for unexplained myopathies or restrictive lung disease. The economic burden of delayed diagnosis and advanced disease management far outweighs the cost of early, targeted screening.

The goal is to shift the diagnostic paradigm from reactive to proactive. Clinicians should consider LOPD in any patient with progressive, unexplained respiratory insufficiency, even in the absence of profound motor deficits. This vigilance could significantly shorten the diagnostic timeline, allowing for earlier intervention and a better prognosis for patients living with this debilitating rare disease.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Labella B, Cotti Piccinelli S, Risi B, et al. A Comprehensive Update on Late-Onset Pompe Disease. Biomolecules. 2023;13(9). doi:10.3390/biom13091279

2.

2. Schoser B, van der Beek NAME, Broomfield A, et al. Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024. Eur J Neurol. 2024;31(9):e16383. doi:10.1111/ene.16383

3. 3. Khan M, Awan Z, Ali EA, et al. New advances in treating late-onset Pompe Disease: A narrative review. Eur J Pediatr. 2025;185(1):41. doi:10.1007/s00431-025-06669-6

4. 4. Teener JW. Late-onset Pompe's disease. Semin Neurol. 2012;32(5):506-11. doi:10.1055/s-0033-1334469

5. 5. Boueri M, Doxey J, Boggs T, et al. Lessons from late-onset Pompe disease identified by Newborn screening: A systematic review. Mol Genet Metab. 2026;147(4):109762. doi:10.1016/j.ymgme.2026.109762

6. 6. Maulet T, Bonnyaud C, Weill C, Laforêt P, Cattagni T. Motor Function Characteristics of Adults With Late-Onset Pompe Disease: A Systematic Scoping Review. Neurology. 2023;100(1):e72-e83. doi:10.1212/WNL.0000000000201333

LICENCE & RIGHTS

MEDICAL DISCLAIMER